Co-founder and international co-ordinator Associazione Luca Coscioni shares his thoughts on the outlook for the campaign.
Leaders in the fields of psychedelics and cannabis will join together for the GCI Virtual Summit.
In a bid to help bring DMT and 5-MeO-DMT to patients, Biomind Labs has completed the development of its novel nasal gel delivery system.
A new study has been launched to investigate the effects of LSD microdosing on sleep and cognitive measures.
A group of experts gathered to discuss microdosing and separate the fact from the fiction regarding the safety and efficacy of the practice.
Awakn has signed a Memorandum of Understanding (MOU) with the Devon Partnership NHS Trust and the University of Exeter to increase access to psychedelic-assisted therapy for...
The non-profit Mind Medicine Australia will be hosting the summit that will bring together leaders in the field of psychedelics to discuss the benefits of the...
Diamond Therapeutics has now dosed the first cohort of its Phase I low-dose psilocybin clinical trial.
A study undertaken over a five-year period has shown that a single dose of ketamine improved thinking and reasoning in people who had expressed thoughts of...
A small study has reported that two doses of psilocybin received with supportive psychotherapy relieves depression.
For the multi-site open-label extension study of MDMA-assisted psychotherapy for PTSD (MAPPUSX) sponsored by MAPS, Numinus will manage two new clinics in Montreal and Vancouver.
The largest psilocybin therapy clinical trial ever conducted, investigating psilocybin for treatment-resistant depression (TRD), has achieved its primary endpoint.
Kicking off the Microdose Wonderland conference in Miami, Cybin Inc announced it will be moving its psilocybin analogue – CYB003 – into clinical trials.